Watson Pharma (WPI) Affirms Delaware Court of Appeals Ruling that Sanctura XR Patents are Invalid

Article Stock Quotes (1) Comments (0)

Watson Pharmaceuticals, Inc. (NYSE: WPI) confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid. Watson's Abbreviated New Drug Application for a generic version of Sanctura XR® is pending with the Food and Drug Administration.

Sanctura XR® is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. For the twelve months ending April 30, 2012, Sanctura XR® had total U.S. sales of approximately $66 million, according to IMS Health data.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Brocade (BRCD), A10 Settle Litigation; Brocade to Get $5M Cash, $70M Conv. Note
• Janssen Pharma (JNJ) Plans Slew of Filing, Extension Submissions by FY17
• Dean Foods (DF) Completes WhiteWave (WWAV) Spin-Off

Create E-mail Alert Related Categories

Corporate News, FDA, Litigation

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?